person · Reporting owner

Connaughton Bernadette

Disclosed activity across 3 companies

Tapewire entity: 24717
SEC CIK: 0001662521

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Editas Medicine, Inc.EDIT · Entity 5502	Director	June 17, 2026	June 22, 2026
HALOZYME THERAPEUTICS, INC.HALO · Entity 793	Director	May 05, 2026	October 08, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Editas Medicine, Inc.

Report date June 17, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2036-06-16	Direct	51,700	Reported balance After 2026-06-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-17 · Grant · Acquired 51,700 · Balance 51,700 F1: This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027.

HALOZYME THERAPEUTICS, INC.

Report date May 05, 2026 · Filed October 08, 2026 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	42,294	Reported balance After 2026-05-05 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2026-05-05 · Grant · Acquired 3,796 · Balance 42,294 F1: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. F2: This Form 4/A amends the Form 4 filed on May 7, 2026 solely to correct the number of RSUs acquired and the amount of securities beneficially owned following the reported transaction. The original filing reported 6,796 RSUs acquired. The correct number of RSUs acquired was 3,796. As a result, the amount of securities beneficially owned following the transaction has been revised accordingly.

Filing footnotes · ownership attribution and instrument terms

F1: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.

F2: This Form 4/A amends the Form 4 filed on May 7, 2026 solely to correct the number of RSUs acquired and the amount of securities beneficially owned following the reported transaction. The original filing reported 6,796 RSUs acquired. The correct number of RSUs acquired was 3,796. As a result, the amount of securities beneficially owned following the transaction has been revised accordingly.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Syneos Health, Inc.

Report date September 28, 2023 · Filed September 28, 2023

Section 16 reporting ended · disclosed 2023-09-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2023-09-28 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2023-09-28 · Disposition to issuer · Disposed 9,915 · Balance 4,863 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. Row 2 · 2023-09-28 · Disposition to issuer · Disposed 4,863 · Balance 0 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. F2: In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the "Effective Time") and as a result of the Merger each award of restricted stock units ("RSUs") and performance stock units ("PSUs") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the "Specified Awards")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a "Contingent Cash Award") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance or based on the actual level of achievement of performance goals, F3: continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for "cause" or by the holder without "good reason," in either case prior to the first anniversary of the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes.

F2: In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the "Effective Time") and as a result of the Merger each award of restricted stock units ("RSUs") and performance stock units ("PSUs") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the "Specified Awards")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a "Contingent Cash Award") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance or based on the actual level of achievement of performance goals,

F3: continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for "cause" or by the holder without "good reason," in either case prior to the first anniversary of the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 10, 2026 Filed Aug 11, 2026 21:43 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	SaleCommon Stock	1,626	$102.80	$167,152.80	Disclosure SEC source: 0001662521-26-000002 · wk-form4_1786484634.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,418 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1. Read SEC document
July 01, 2026 Filed Jul 2, 2026 20:42 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	SaleCommon Stock	625	$77.21	$48,255.63	Disclosure SEC source: 0001159036-26-000094 · wk-form4_1783024925.xml · nonDerivative · entry 2 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,044 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1. F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $76.950 to $77.710. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
July 01, 2026 Filed Jul 2, 2026 20:42 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	SaleCommon Stock	1,000	$76.40	$76,395.00	Disclosure SEC source: 0001159036-26-000094 · wk-form4_1783024925.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,669 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $75.930 to $76.850. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
June 17, 2026 Filed Jun 22, 2026 20:31 UTC	Editas Medicine, Inc. EDIT · Entity 5502	GrantStock Option (right to buy) · Derivative	51,700	$0.00 Strike: $2.55	$0.00	Disclosure SEC source: 0001650664-26-000072 · wk-form4_1782160274.xml · derivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,700 Underlying: Common Stock · 51,700 shares Expires 2036-06-16 F1 · derivative.exercise_date: This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027. Read SEC document
June 01, 2026 Filed Jun 2, 2026 21:20 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	SaleCommon Stock	1,625	$66.21	$107,591.25	Disclosure SEC source: 0001159036-26-000072 · wk-form4_1780435230.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,669 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1. Read SEC document
May 05, 2026 Filed Oct 8, 2026 23:55 UTC Amendment	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	GrantCommon Stock	3,796	$0.00	$0.00	Disclosure SEC source: 0001159036-26-000139 · wk-form4a_1791503732.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,294 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. F2 · shares: This Form 4/A amends the Form 4 filed on May 7, 2026 solely to correct the number of RSUs acquired and the amount of securities beneficially owned following the reported transaction. The original filing reported 6,796 RSUs acquired. The correct number of RSUs acquired was 3,796. As a result, the amount of securities beneficially owned following the transaction has been revised accordingly. F2 · balance_after: This Form 4/A amends the Form 4 filed on May 7, 2026 solely to correct the number of RSUs acquired and the amount of securities beneficially owned following the reported transaction. The original filing reported 6,796 RSUs acquired. The correct number of RSUs acquired was 3,796. As a result, the amount of securities beneficially owned following the transaction has been revised accordingly. Read SEC document
May 05, 2026 Filed May 7, 2026 23:01 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	GrantOption to Purchase Common Stock · Derivative	6,040	$0.00 Strike: $65.87	$0.00	Disclosure SEC source: 0001159036-26-000059 · wk-form4_1778194891.xml · derivative · entry 2 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,040 Underlying: Common Stock · 6,040 shares Expires 2036-05-05 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document
May 05, 2026 Filed May 7, 2026 23:01 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	GrantCommon Stock	6,796	$0.00	$0.00	Disclosure SEC source: 0001159036-26-000059 · wk-form4_1778194891.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,294 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document
May 01, 2026 Filed May 5, 2026 21:05 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	SaleCommon Stock	1,625	$63.48	$103,155.00	Disclosure SEC source: 0001159036-26-000055 · wk-form4_1778015107.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,498 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1. Read SEC document
January 05, 2026 Filed Jan 6, 2026 23:55 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	SaleCommon Stock	2,000	$70.25	$140,500.00	Disclosure SEC source: 0001159036-26-000006 · wk-form4_1767743752.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,123 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1. Read SEC document
December 01, 2025 Filed Dec 2, 2025 00:50 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	SaleCommon Stock	829	$71.60	$59,356.40	Disclosure SEC source: 0001159036-25-000065 · wk-form4_1764636645.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,123 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1. Read SEC document
November 10, 2025 Filed Nov 12, 2025 22:58 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	SaleCommon Stock	2,000	$68.48	$136,960.00	Disclosure SEC source: 0001159036-25-000052 · wk-form4_1762988298.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,952 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1. Read SEC document
October 01, 2025 Filed Oct 1, 2025 22:29 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	SaleCommon Stock	500	$75.70	$37,852.00	Disclosure SEC source: 0001662521-25-000005 · form4-10012025_101031.xml · nonDerivative · entry 2 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,952 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1. F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $75.64 to $75.92. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
October 01, 2025 Filed Oct 1, 2025 22:29 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	SaleCommon Stock	1,500	$75.09	$112,629.00	Disclosure SEC source: 0001662521-25-000005 · form4-10012025_101031.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,452 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $74.64 to $75.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
September 02, 2025 Filed Sep 3, 2025 00:11 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	SaleCommon Stock	923	$74.11	$68,404.45	Disclosure SEC source: 0001415889-25-023470 · form4-09032025_120938.xml · nonDerivative · entry 3 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,952 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1. F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $73.95 to $74.38. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
September 02, 2025 Filed Sep 3, 2025 00:11 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	SaleCommon Stock	2,977	$73.62	$219,160.79	Disclosure SEC source: 0001415889-25-023470 · form4-09032025_120938.xml · nonDerivative · entry 2 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,875 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $72.91 to $73.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
September 02, 2025 Filed Sep 3, 2025 00:11 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	SaleCommon Stock	100	$71.71	$7,171.00	Disclosure SEC source: 0001415889-25-023470 · form4-09032025_120938.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,852 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1. Read SEC document
June 06, 2025 Filed Jun 10, 2025 20:18 UTC	Editas Medicine, Inc. EDIT · Entity 5502	GrantStock Option (right to buy) · Derivative	37,500	$0.00 Strike: $1.91	$0.00	Disclosure SEC source: 0001650664-25-000100 · wk-form4_1749586697.xml · derivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2035-06-05 F1 · derivative.exercise_date: This option was granted on June 6, 2025 and is scheduled to vest in full on June 6, 2026. Read SEC document
May 01, 2025 Filed May 2, 2025 20:02 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	GrantOption to Purchase Common Stock · Derivative	5,750	$0.00 Strike: $60.03	$0.00	Disclosure SEC source: 0001415889-25-011767 · form4-05022025_080528.xml · derivative · entry 2 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,750 Underlying: Common Stock · 5,750 shares Expires 2035-05-01 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document
May 01, 2025 Filed May 2, 2025 20:02 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	GrantCommon Stock	4,165	$0.00	$0.00	Disclosure SEC source: 0001415889-25-011767 · form4-05022025_080528.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,952 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document
May 30, 2024 Filed Jun 3, 2024 20:25 UTC	Editas Medicine, Inc. EDIT · Entity 5502	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $5.17	$0.00	Disclosure SEC source: 0001650664-24-000056 · wk-form4_1717446325.xml · derivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-05-29 F1 · derivative.exercise_date: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025. Read SEC document
April 25, 2024 Filed Apr 29, 2024 21:51 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	GrantOption to Purchase Common Stock · Derivative	8,804	$0.00 Strike: $38.46	$0.00	Disclosure SEC source: 0001415889-24-011679 · form4-04292024_090416.xml · derivative · entry 2 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,804 Underlying: Common Stock · 8,804 shares Expires 2034-04-25 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document
April 25, 2024 Filed Apr 29, 2024 21:51 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	GrantCommon Stock	6,501	$0.00	$0.00	Disclosure SEC source: 0001415889-24-011679 · form4-04292024_090416.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,787 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document
September 28, 2023 Filed Sep 28, 2023 17:05 UTC	Syneos Health, Inc. SYNH · Entity 109360	Disposition to issuerClass A Common Stock	4,863	$0.00	$0.00	Disclosure SEC source: 0001209191-23-050772 · doc4.xml · nonDerivative · entry 2 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. F2 · price: In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the "Effective Time") and as a result of the Merger each award of restricted stock units ("RSUs") and performance stock units ("PSUs") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the "Specified Awards")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a "Contingent Cash Award") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance or based on the actual level of achievement of performance goals, F3 · price: continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for "cause" or by the holder without "good reason," in either case prior to the first anniversary of the Effective Time. Read SEC document
September 28, 2023 Filed Sep 28, 2023 17:05 UTC	Syneos Health, Inc. SYNH · Entity 109360	Disposition to issuerClass A Common Stock	9,915	$43.00	$426,345.00	Disclosure SEC source: 0001209191-23-050772 · doc4.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,863 F1 · price: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. Read SEC document
June 01, 2023 Filed Jun 5, 2023 20:30 UTC	Editas Medicine, Inc. EDIT · Entity 5502	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $9.55	$0.00	Disclosure SEC source: 0001415889-23-009236 · form4-06052023_040621.xml · derivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-05-31 F1 · derivative.exercise_date: This option was granted on June 1, 2023 and is scheduled to vest in full on June 1, 2024. Read SEC document
May 25, 2023 Filed May 30, 2023 17:14 UTC	Syneos Health, Inc. SYNH · Entity 109360	GrantClass A Common Stock	4,863	$0.00	$0.00	Disclosure SEC source: 0001209191-23-032940 · doc4.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,778 F1 · shares: Represents an award of restricted stock units that vests in full one year from the grant date, or, if earlier, the date of the 2024 annual meeting of stockholders but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors. Read SEC document
May 05, 2023 Filed May 9, 2023 22:12 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	GrantOption to Purchase Common Stock · Derivative	11,371	$0.00 Strike: $31.00	$0.00	Disclosure SEC source: 0001415889-23-007688 · form4-05092023_100557.xml · derivative · entry 2 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,371 Underlying: Common Stock · 11,371 shares Expires 2033-05-05 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document
May 05, 2023 Filed May 9, 2023 22:12 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	GrantCommon Stock	8,065	$0.00	$0.00	Disclosure SEC source: 0001415889-23-007688 · form4-05092023_100557.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,286 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director. Read SEC document
November 16, 2022 Filed Nov 17, 2022 22:10 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	GiftCommon Stock	5,998	$0.00	$0.00	Disclosure SEC source: 0001415889-22-011511 · form4-11172022_101138.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,221 F1 · kind: Represents a bona fide gift to charity. Read SEC document
June 09, 2022 Filed Jun 13, 2022 20:30 UTC	Editas Medicine, Inc. EDIT · Entity 5502	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $12.31	$0.00	Disclosure SEC source: 0001415889-22-006494 · form4-06132022_040635.xml · derivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: This option was granted on June 9, 2022 and is scheduled to vest in full on June 9, 2023. Read SEC document
May 25, 2022 Filed May 27, 2022 17:03 UTC	Syneos Health, Inc. SYNH · Entity 109360	GrantClass A Common Stock	2,839	$0.00	$0.00	Disclosure SEC source: 0001209191-22-032624 · doc4.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,915 F1 · shares: Represents an award of restricted stock units that vests in full one year from the grant date, or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors. Read SEC document
May 05, 2022 Filed May 7, 2022 00:04 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	GrantRestricted Stock Units	6,206	$0.00	$0.00	Disclosure SEC source: 0001179110-22-002907 · edgar.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,219 F1 · shares: Represents annual restricted stock unit grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2023 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document
October 26, 2021 Filed Oct 28, 2021 20:13 UTC	Editas Medicine, Inc. EDIT · Entity 5502	GrantStock Option (right to buy) · Derivative	24,732	$0.00 Strike: $37.90	$0.00	Disclosure SEC source: 0001179110-21-009688 · edgar.xml · derivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,732 Underlying: Common Stock · 24,732 shares Expires 2031-10-25 F1 · derivative.exercise_date: This option was granted on October 26, 2021 and is scheduled to vest over three years in equal yearly installments of one-third of the shares beginning on October 26, 2022 through October 26, 2024. Read SEC document
May 12, 2021 Filed May 14, 2021 17:06 UTC	Syneos Health, Inc. SYNH · Entity 109360	GrantClass A Common Stock	2,364	$0.00	$0.00	Disclosure SEC source: 0001209191-21-032806 · doc4.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,076 F1 · shares: Represents an award of restricted stock units that vests in full one year from the grant date, or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors. Read SEC document
May 05, 2021 Filed May 7, 2021 00:01 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	GrantRestricted Stock Units	5,230	$0.00	$0.00	Disclosure SEC source: 0001179110-21-004970 · edgar.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,013 F1 · shares: Represents annual restricted stock unit grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2022 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document
May 27, 2020 Filed May 29, 2020 17:02 UTC	Syneos Health, Inc. SYNH · Entity 109360	GrantClass A Common Stock	2,803	$62.43	$174,991.29	Disclosure SEC source: 0001610950-20-000102 · wf-form4_159078614606488.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,712 F1 · shares: Represents an award of restricted stock units which vests in full one year from the grant date, or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors. Read SEC document
April 30, 2020 Filed May 1, 2020 23:10 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	GrantCommon Stock	8,829	$0.00	$0.00	Disclosure SEC source: 0001179110-20-005376 · edgar.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,783 F1 · shares: Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 30, 2021 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document
November 12, 2019 Filed Nov 14, 2019 16:22 UTC	Syneos Health, Inc. SYNH · Entity 109360	GrantClass A Common Stock	1,909	$49.48	$94,457.32	Disclosure SEC source: 0001610950-19-000057 · wf-form4_157376655281836.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,909 F1 · shares: Represents an award of restricted stock units which vests in full one year from the grant date, subject to continued service on the Issuer's Board of Directors or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting. Read SEC document
May 02, 2019 Filed May 3, 2019 20:10 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	GrantCommon Stock	12,173	$0.00	$0.00	Disclosure SEC source: 0001179110-19-005499 · edgar.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,954 F1 · shares: Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 2, 2020 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document
September 07, 2018 Filed Sep 11, 2018 22:24 UTC	HALOZYME THERAPEUTICS, INC. HALO · Entity 793	GrantCommon Stock	5,781	$0.00	$0.00	Disclosure SEC source: 0001179110-18-011307 · edgar.xml · nonDerivative · entry 1 Connaughton Bernadette · CIK 0001662521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,781 F1 · shares: Represents initial restricted stock grant upon becoming a member of the Company's Board of Directors pursuant to the Director's Compensation Program. This grant will vest on the date of the Company's 2019 annual meeting of stockholders. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.